Patents by Inventor Jennifer Brogdon

Jennifer Brogdon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20160096892
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
    Type: Application
    Filed: July 21, 2015
    Publication date: April 7, 2016
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NOVARTIS AG
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Glass, Thomas Huber, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Huijuan Song, Qilong Wu, Jiquan Zhang
  • TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20160068601
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Application
    Filed: August 19, 2015
    Publication date: March 10, 2016
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NOVARTIS AG
    Inventors: Jennifer Brogdon, Saar Gill, David Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • TREATMENT OF CANCER USING A CLL-1 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20160051651
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
    Type: Application
    Filed: July 21, 2015
    Publication date: February 25, 2016
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NOVARTIS AG
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Glass, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • TREATMENT OF CANCER USING HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20160046724
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Application
    Filed: July 21, 2015
    Publication date: February 18, 2016
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NOVARTIS AG
    Inventors: Jennifer Brogdon, Eugene Choi, Hilmar Erhard Ebersbach, David Glass, Heather Huet, Carl H. June, Joan Mannick, Michael C. Milone, Leon Murphy, Gabriela Plesa, Celeste Richardson, Marco Ruella, Reshma Singh, Yongqiang Wang, Qilong Wu
  • TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20150283178
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
    Type: Application
    Filed: April 7, 2015
    Publication date: October 8, 2015
    Inventors: Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20150004168
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: June 18, 2014
    Publication date: January 1, 2015
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Igor SPLAWSKI, Jennifer BROGDON, Joshua GOLDSTEIN, William DOLE, John TRAUGER, Chonghui ZHANG
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20140377281
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: June 18, 2014
    Publication date: December 25, 2014
    Applicant: NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Jennifer BROGDON, William DOLE, John TRAUGER, Yuting TANG, Julia NEUGEBAUER, Annika SCHMID
  • EFFECTIVE TARGETING OF PRIMARY HUMAN LEUKEMIA USING ANTI-CD123 CHIMERIC ANTIGEN RECEPTOR ENGINEERED T CELLS
    Publication number: 20140322212
    Abstract: The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML) and B-cell acute lymphoid leukemia (B-ALL). The invention also relates to at least one chimeric antigen receptor (CAR) specific to CD123, vectors comprising the same, and recombinant T cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD123 binding domain. The invention also includes methods of bone marrow ablation for use in treatments necessitating bone marrow reconditioning or transplant.
    Type: Application
    Filed: February 20, 2014
    Publication date: October 30, 2014
    Inventors: Jennifer Brogdon, Saar Gill, Carl H. June, Michael D. Kalos, Andreas Loew, John Scholler
  • TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20140322275
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
    Type: Application
    Filed: February 20, 2014
    Publication date: October 30, 2014
    Inventors: Jennifer Brogdon, Laura Alexandra Johnson, Carl H. June, Andreas Loew, Marcela Maus, John Scholler, Hideho Okada
  • TREATMENT OF CANCER USING HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20140271635
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.
    Type: Application
    Filed: March 15, 2014
    Publication date: September 18, 2014
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NOVARTIS AG
    Inventors: Jennifer Brogdon, Carl H. June, Andreas Loew, Marcela Maus, John Scholler